- Molecular basis of prostate and renal cancer development and progression
- Novel biomarkers and tumor-based targets for chemoprevention and treatment
- Stromal and host factors in prostate and renal cancer including inflammation, immunomodulation and angiogenesis
- Translational research and novel investigator-initiated clinical trials
The overarching goal of the GU Malignancies Program is to explore fundamental biologic pathways of critical importance to the development and progression of prostate and renal cancer and to foster translational, investigator-initiated clinical trials to advance therapeutic options.
To provide additional structure and promote cohesion within the larger Program, investigators have been further organized around two scientific focus areas:
- Prostate Cancer - includes genetic susceptibility and molecular basis, chemoprevention, molecular biomarkers of prognosis and therapeutic targeting of the IGF and PI3K/Akt/mTOR axis
- Renal Cancer - includes molecular and clinical biomarkers of prognosis, response and resistance; immunomodulatory effects of treatment, and therapeutic targeting of angiogenesis and the PI3K/Akt/mTOR axis